irs program accomplishments · form 990 part iii · fy2024
What they reported doing
- #1 primary $2.15MPRODUCT INTRODUCTION AND ACCESS: THE PRODUCT INTRODUCTION PROGRAM IS DESIGNED TO IDENTIFY AND ANTICIPATE NEEDS AND GAPS AND PROVIDE TARGETED TOOLS, SUPPORT AND PLATFORMS TO EXPAND ACCESS TO HIV/AIDS PREVENTION. THE PROGRAM FOCUSES ON: SUCCESSFUL SCALE-UP AND INTRODUCTION IN THREE PRIORITY COUNTRIES FROM THE OUTSET; DEVELOP ADAPTABLE AND SCALABLE TOOLS TO SUPPORT OTHER COUNTRIES; SUPPORT THE DEVELOPMENT OF MARKETABLE PRODUCTS IN THE HIV PREVENTION AND SEXUAL AND REPRODUCTIVE HEALTH RESEARCH PIPELINE; AND CREATE A FLEXIBLE MECHANISM TO ASSIST PRODUCT DEVELOPERS, FUNDERS AND COUNTRY PROGRAMS TO IDENTIFY AND ADDRESS BARRIERS TO IMPROVED PRODUCTS AND ACCELERATED INTRODUCTION. PROJECTS ARE IMPLEMENTED IN COLLABORATION WITH A NETWORK OF FUNDERS, (CONTINUED ON SCHEDULE O)CONTINUED: PRODUCT DEVELOPERS AND GOVERNMENTAL AND NON-GOVERNMENTAL ORGANIZATIONS INCLUDING THE BILL AND MELINDA GATES FOUNDATION, CHILDRENS INVESTMENT FUND FOUNDATION, WORLD HEALTH ORGANIZATION, POPULATION COUNCIL, VIATRIS, MANN GLOBAL HEALTH, MEDICINES360, USAID, CATALYST GLOBAL, HIV PREVENTION TRIALS NETWORK, AND CLINTON HEALTH ACCESS INITATIVE.
- #2 $1.54MGLOBAL MOVEMENT BUILDING: GLOBAL MOVEMENT BUILDING CULTIVATES THE NEXT GENERATION OF ADVOCATES VIA THE AVAC FELLOWS AND ADVOCACY NAVIGATOR PROGRAMS. ADVOCATES ARE EQUIPPED WITH THE SKILLS, OPPORTUNITIES AND ACCESS TO DRIVE CHANGE IN HIV PREVENTION AND GLOBAL HEALTH EQUITY BY AMPLIFYING COMMUNITY VOICES AND INFLUENCING POLICY AND RESEARCH. ALUMNI OF THESE PROGRAMS ARE LEADING, INTERNATIONALLY RECOGNIZED CIVIL SOCIETY ADVOCATES. THEY HAVE GONE ON TO FOUND CIVIL SOCIETY ORGANIZATIONS, INFLUENCE THE HIV PREVENTION RESEARCH PIPELINE, AND SHAPE CONVERSATIONS AND OBJECTIVES IN THE FIELD. AVAC ALSO SHAPES THE MEDIA ENVIRONMENT BY COLLABORATING CLOSELY WITH JOURNALIST CONVENERS TO BRING TOGETHER JOURNALISTS AND SCIENTISTS AT MEDIA SCIENCE CAFES. THROUGH THIS ENGAGEMENT WITH EXPERTS, (CONTINUED ON SCHEDULE O)CONTINUED: LOCAL JOURNALISTS HAVE DIRECT ACCESS TO ACCURATE DATA AND INFORMATION, ENABLING THEM TO TRANSLATE THE SCIENCE AND REPORT DIRECTLY TO LOCAL COMMUNITIES ON DEVELOPMENTS IN HIV BIOMEDICAL PREVENTION RESEARCH. THIS IMPROVES THE QUALITY AND ACCURACY OF REPORTING, COMBATS MISINFORMATION, AND BRINGS VISIBILITY TO RESEARCH DEVELOPMENTS.
named programs · 5 · from sources
What they call their work
Global Movement Building
Trains and supports next-generation advocates through the AVAC Fellows and Advocacy Navigator programs; enhances media engagement through Science Cafes that connect journalists and scientists.
Implementation Advocacy
Provides technical support to improve donor and government investments in comprehensive, rights-based HIV/AIDS responses.
Policy Advocacy
Advances national and global HIV prevention agendas through evidence-based, community-supported advocacy; mobilizes funding and shapes health spending policies with a focus on equity and inclusion.
Product Introduction and Access
Identifies gaps and develops scalable tools to expand access to HIV prevention products in priority countries; supports product developers and country programs in overcoming barriers to introduction.
Research Engagement and Preparedness
Shapes the HIV R&D environment through advocacy, stakeholder convenings, and subgrants to partners; promotes investment and ethical research practices in biomedical prevention.
activities · 4 groups
What they do
-
HIV Research and Advocacy Funding 3 activities
- Advocacy for equitable HIV prevention and global health equityAdvocates for the ethical development, equitable delivery, and faster rollout of effective HIV prevention options—including PrEP, treatment as prevention (U=U), condoms, and testing—as part of a broader agenda for global health equity. Develops and advances national, regional, and international policy agendas in collaboration with partners.
- Capacity building for community and advocate leadership in HIV responseBuilds global advocacy capacity through training programs such as the AVAC Fellows and Advocacy Navigator initiatives, equipping emerging leaders—especially from affected communities—to influence HIV prevention research, policy, and implementation.
- Grantmaking to support HIV vaccine and prevention research and accessFunds partner organizations through subgrants to eliminate barriers to HIV vaccine development and access, supporting biomedical prevention research and advocacy efforts in the U.S. and Africa.
-
-
International Emergency Medical Relief 1 activity
- Legal advocacy to protect global health fundingSued U.S. federal entities including the State Department, USAID, and Presidential Administration to challenge a freeze on foreign aid funding for global health programs, resulting in court-ordered release of millions in frozen assistance for HIV and other critical programs.
-
-
Medical Research & Education Dissemination 1 activity
- Public education and information dissemination on HIV preventionProduces and distributes accessible public resources including the PxPulse podcast, NewsDigest, PxWire, STIWatch newsletter, and a resource database to improve understanding of biomedical HIV prevention, research developments, and implementation issues.
-
-
Biomedical Research and Innovation 1 activity
- Research and analysis in HIV prevention science and pipeline trackingConducts research and produces analyses, infographics, and public-facing tools to map the HIV prevention and long-acting antiretroviral (LA-ART) research pipelines, track product development timelines, analyze PEPFAR data, assess market readiness, and visualize gaps in donor commitments and access. Maintains a public tracker of the long-acting HIV treatment pipeline.
-
financials · form 990 · fy2024
revenue
Total revenue$10.03M
Contributions & grants$9.96M99%
Program service revenue$00%
Investment income$62K1%
Other revenue$11K
expenses
Total expenses$13.79M
Program expenses81%
Admin / overhead19%
Fundraising0%
Salaries & benefits$7.75M
Grants paid out$3.02M
Largest expense lineCompensation
balance sheet
Total assets$3.85M
Cash$2.69M
Investments$503K
Liabilities$895K
Net assets$2.96M
Liquid reserves2.8 mo
3 years on record · 2020–2024 · YoY revenue -32.3%
leadership · form 990 part vii · fy2024
Who runs it
paid leadership · 8
| Name | Title | Hours/wk | Compensation |
|---|---|---|---|
| MITCHELL WARREN | EXECUTIVE DIRECTOR | 50 | $448K |
| ERIN KIERNON | CHIEF OPERATING OFFICER | 40 | $318K |
| ABIGAIL SMITH | CHIEF FINANCIAL OFFICER | 40 | $303K |
| STACEY HUMPHRIES | DIRECTOR, RESEARCH ENGAGEMENT | 40 | $253K |
| SURAJKUMAR MADOORI | DIRECTOR, POLICY ADVOCACY | 40 | $239K |
| MANJU CHATANI-GADA | DIRECTOR, PARTNERSHIPS | 40 | $239K |
| WANDA BUCKNER | DIRECTOR, FINANCE | 40 | $230K |
| KENYON FARROW | DIRECTOR, COMMUNICATIONS | 40 | $199K |
board members · 15
- ADRIAN MCDERMOTT — BOARD MEMBER
- BLAIR HANEWALL — PRESIDENT
- CATE HANKINS — BOARD MEMBER
- DEONDRE MOORE — BOARD MEMBER
- JEFF O'MALLEY — BOARD MEMBER
- JESSE MILAN — BOARD MEMBER
- JINTANAT ANANWORANICH — BOARD MEMBER
- KELLY MCKAIG — TREASURER
- LEIGH ANN VAN DER MERWE — BOARD MEMBER
- LINDA-GAIL BEKKER — BOARD MEMBER
- MARINA CASKEY — BOARD MEMBER
- NYARADZO MGODI — BOARD MEMBER
- SOLANGE BAPTISTE — BOARD MEMBER
- SUSIE MCLEAN — BOARD MEMBER
- YVONNE MUTHONI — SECRETARY
relationships · 67
Who they work with
- AVAC Network — Organization refers to itself as AVAC, indicating use of acronym as part of organizational identity.
- Access Bridge Partner — Collaborated with Access Bridge on discussions around real-world access to long-acting PrEP, including use of case narratives like “Amani” to illustrate systemic barriers.
- Access Bridge Partner — Jointly issued a statement applauding Merck's licensing announcement and calling for equitable access to alimatravir.
- Avenir Health Partner — Subgrantee under USAID-funded HIV biomedical prevention research project
- Bill and Melinda Gates Foundation Partner — Collaborates on product introduction and access initiatives for HIV prevention technologies
- Bluesky Partner — Social media platform used for outreach and engagement
- Brazil Ministry of Health Government — Engaged with statements from Brazil’s Minister of Health at the AIDS 2026 conference opening.
- CAPRISA Partner — Collaborates with CAPRISA on HIV prevention research and shares findings from joint scientific efforts.
- CCI Partner — Subgrantee under USAID-funded HIV biomedical prevention research project
- CLI Partner — Subgrantee under USAID-funded HIV biomedical prevention research project
- Catalyst Global Partner — Partner in product introduction and access initiatives
- Children's Investment Fund Foundation Partner — Partner in product introduction and access initiatives for HIV prevention
- Clinton Health Access Initiative Partner — Partner in scaling up access to HIV prevention products
- Coalition to Accelerate and Support Prevention Research Partner — Collaborates with AVAC on the PxPulse project to explore HIV prevention research topics.
- Committee on Homeland Security & Governmental Affairs Government — AVAC submitted a letter to this U.S. Congressional committee regarding the politicization of science and support for Dr. Anthony S. Fauci.
- FHI 360 Partner — Subgrantee under USAID-funded HIV biomedical prevention research project
- Facebook Partner — Social media platform used for outreach and engagement
- Gates Foundation Partner — Engaged with Gates Foundation representatives in shared advocacy for integrated delivery of long-acting antiretrovirals and global access to innovations.
- Global Black Gay Men Connect (GBGMC) Partner — Co-hosted satellite sessions at AIDS 2026 focused on access to long-acting HIV prevention for key populations in sub-Saharan Africa.
- Global Fund Partner — Engages with joint announcements on scaling up lenacapavir for PrEP.
- Global Health Council Coalition — Led a parallel lawsuit challenging the same foreign aid freeze, part of coordinated legal action.
- Good Participatory Practice Guidelines Partner — AVAC champions the Good Participatory Practice (GPP) Guidelines and integrates them into prevention research and policy advocacy.
- Good Participatory Practice Guidelines Partner — Champions the Good Participatory Practice Guidelines to strengthen community engagement in research and policy.
- HEJNU Partner — Subgrantee under USAID-funded HIV biomedical prevention research project
- HIV Prevention Trials Network Partner — Collaborates on research engagement and product development efforts
- HIV/AIDS Vaccine Ethics Group of the University of KwaZulu - Natal (HAVEG) Partner — Subgrantee under USAID-funded HIV biomedical prevention research project in South Africa
- Health GAP Partner — Subgrantee under USAID-funded HIV biomedical prevention research project
- ICW-EA Partner — Subgrantee under USAID-funded HIV biomedical prevention research project
- ITPC Partner — Collaborates with ITPC on governance of emerging technologies, including AI in public health, with shared emphasis on community oversight.
- Instituto Medicina Social (IMS/UERJ) Partner — Participates in panel discussions on health equity and public health research.
+ 37 more
strategies · 5
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.
- Community-Centered Research and Advocacymethodology: community-centered_researchBy integrating community perspectives into research design and policy advocacy, the organization improves the relevance, ethical integrity, and uptake of HIV prevention innovations because community leadership builds trust and ensures responsiveness to affected populations.
- Early and Iterative Access Planningmethodology: early_access_planningBy engaging stakeholders and communities early in clinical development, the organization enables equitable rollout of new prevention tools because access strategies co-developed during trials are more likely to succeed at scale.
- Good Participatory Practice for Accountabilitymethodology: good_participatory_practiceBy promoting Good Participatory Practice Guidelines and linking decision-makers with trained community advocates, the organization ensures accountability in HIV prevention research and policy because structured community engagement leads to more ethical and effective outcomes.
- Integrated Science and Delivery with Equitymethodology: integration_of_science_and_delivery_systemsBy combining scientific innovation with robust, person-centered delivery systems, the organization achieves equitable impact in HIV prevention because breakthroughs only lead to public health gains when access is proactively designed for speed, scale, and equity.
- Science Translation to Drive Advocacymethodology: science_translation_and_advocacyBy translating complex scientific, funding, and policy information into accessible formats, the organization identifies strategic advocacy opportunities because informed communities and stakeholders are better positioned to influence equitable health policy and innovation.